Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma ...

The Saudi Arabia tumor market is a dynamic landscape shaped by advancements in medical technology, evolving treatment approaches, and shifting demographic trends. This market report provides a ...

A study presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition reveals genetic factors that can affect the molecular pathways involved in ...

Dr. Vera will present an overview of Marker’s technology and clinical developments on Thursday, December 12, 2024, at 1:30 PM EST.

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

“POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we ...

By illuminating how diet and other lifestyle factors may affect a person's likelihood of developing a blood disorder as well as disease progression and response to treatment, the studies point to ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...